What’s New in the Management of COVID-19Incorporating New Data and Updated Guidelines Into Daily Practice
Clinical Practice Guidelines
COVID-19 Treatment Guidelines.
National Institutes of Health (NIH).
Test to Treat.
Administration for Strategic Preparedness & Response (ASPR).
Isolation and precautions for people with COVID-19.
Centers for Disease Control and Prevention (CDC).
Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States.
Trends in number of COVID-19 cases and deaths in the US reported to the CDC, by state/territory.
Federal response to COVID-19: therapeutics clinical implementation guide.
Department of Health and Human Services (DHHS).
Fact sheet for healthcare providers: emergency use authorization for Lagevrio™ (molnupiravir).
US Food and Drug Administration (FDA).
Fact sheet for healthcare providers: emergency use authorization for PaxlovidTM.
Highlights of prescribing information: Veklury® (remdesivir).
Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir/ritonavir.
Akinosoglou K, Schinas G, Gogos C. Viruses. 2022;14(11):2540.
Influence of social and cultural factors on the decision to consent for monoclonal antibody treatment among high-risk patients with mild-moderate COVID-19.
Bierle DM, Ganesh R, Wilker CG, et al. J Prim Care Community Health. 2021;12:21501327211019282.
Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for coronavirus disease 2019 (COVID-19).
Boucau J, Uddin R, Marino C, et al. Clin Infect Dis. 2023;76(3)e526-e529.
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial.
Butler C, Hobbs R, Gbinigie O, et al. Lancet. 2022. [Epub ahead of print]
Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with Covid-19.
Ganatra S, Dani SS, Ahmad J, et al. Clin Infect Dis. 2022. [Epub ahead of print]
Early remdesivir to prevent progression to severe Covid-19 in outpatients.
Gottlieb RL, Vaca CE, Paredes R, et al. N Engl J Med. 2022;386(4):305-315.
Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19.
Hammond J, Leister-Tebbe H, Gardner A, et al. N Engl J Med. 2022;386(15):1397-1408.
At the heart of the matter: unmasking and addressing the toll of COVID-19 on diverse populations.
Haynes N, Cooper LA, Albert MA. Circulation. 2020;142(2):105-107.
Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.
Imai M, Ito M, Kiso M, et al. N Engl J Med. 2023;388(1):89-91.
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients.
Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. N Engl J Med. 2022;386(6):509-520.
Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review.
Notarte KI, Catahay JA, Velasco JV, et al. EClinicalMedicine. 2022;53:101624.
Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
Wang Q, Iketani S, Li Z, et al. Cell. 2023;186(2)279-286.e8.
Incidence of viral rebound after treatment with nirmatrelvir-ritonavir and molnupiravir.
Wong GL, Yip TC, Lai MS, et al. JAMA Netw Open. 2022;5(12):e2245086.
Impact of metabolic syndrome on severity of COVID-19 illness.
Wu S, Zhou K, Misra-Hebert A, et al. Metab Syndr Relat Disord. 2022;20(4):191-198.
Nirmatrelvir and the risk of post-acute sequelae of COVID-19.
Xie Y, Choi T, Al-Aly Z. medRxiv. 2022:2022.2011.2003.22281783.
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
Yue C, Song W, Wang L, et al. Lancet Infect Dis. 2023;23(3):278-280.
Incorporating New Data and Updated Guidelines Into Daily Practice
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
A New Era in Precision Medicine
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
Consensus and Controversies on the Road to Precision Medicine
The PCPs Role in Preventing HIV
Ongoing Monitoring, Pulmonary Rehabilitation, and Individualized Care
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
Debates and Discussions About Personalizing Patient Management
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
From Guideline Recommendations to Daily Clinical Decision-Making
Hot Topics in HBV, HCV, and NASH
Improving Patient Outcomes Through Shared Clinical Decision Making
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
Digging Deep on Shared Decision-Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
Mechanistic Insights and Emerging Treatment Options
A PrEP Primer
A Foundation for Managed Care
A Focus on Exacerbation Prevention
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Unlocking Novel Paths to Patient Care
Maximizing Your Role to Impact Patient Outcomes
Evolving Best Practices for Patient Management
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
Informing the Future of NASH Diagnosis and Assessment
A PEP/PrEP Training Guide for Pharmacists
The Increasing Role of JAK Inhibitors
Shared Decision-making in the Era of Biologics
New Pathways to Patient Management
From Comprehensive Patient Evaluations to Individualized Evidence-based Care
Preventing COPD Exacerbations to Improve Outcomes
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Evolving Best Practices for Pediatric Patients
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
New Pathways to Optimize Patient Outcomes
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
An Updated Clinician’s Guide to Assessment and Management
Debates and Discussions About New Upstream Treatment Avenues
A Case-Based Update on Pediatric Patients
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Best Practices for Screening, Diagnosis, and Management
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies
From the Airway Epithelium to Improved Patient Outcomes
Exercising Best Practices for Hospitalized Patients
Accelerating Diagnosis and Treatment